BioStock has performed a Status Report for Cereno Scientific who develops CS1 – a thrombosis prophylactic drug that strengthens the body’s own immune mechanism instead of inhibiting the coagulation system. The Phase II candidate has the potential to redefine the field of thrombosis prevention. The full report is available below.

[et_bloom_inline optin_id=”optin_4″]